Lu Shan, Jiang Kun, Qin Feng, Lu Xiumei, Li Famei
Department of Analytical Chemistry, Shenyang Pharmaceutical University, Wenhua Road 103#, Shenyang 110016, PR China.
J Pharm Biomed Anal. 2009 Jan 15;49(1):163-7. doi: 10.1016/j.jpba.2008.10.012. Epub 2008 Oct 22.
A rapid, selective and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed to simultaneously determine enalapril and enalaprilat in human plasma. With benazepril as internal standard, sample pretreatment involved in a one-step protein precipitation (PPT) with methanol of 0.2 ml plasma. Analysis was performed on an Ultimate XB-C(18) column (50 mm x 2.1 mm, i.d., 3 microm) with mobile phase consisting of methanol-water-formic acid (62:38:0.2, v/v/v). The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction-monitoring (MRM) mode via electrospray ionization (ESI) source. Each plasma sample was chromatographed within 2.5 min. The linear calibration curves for enalapril and enalaprilat were both obtained in the concentration range of 0.638-255 ng/ml (r(2) > or = 0.99) with the lower limit of quantification (LLOQ) of 0.638 ng/ml. The intra-day precision (R.S.D.) was below 7.2% and inter-day R.S.D. was less than 14%, while accuracy (relative error R.E.) was within +/-8.7 and +/-5.5%, determined from QC samples for enalapril and enalaprilat which corresponded to requirement of the guidance of FDA. The HPLC-MS/MS method herein described was fully validated and successfully applied to the pharmacokinetic study of enalapril maleate capsules in 20 healthy male volunteers after oral administration.
建立了一种快速、选择性和灵敏的高效液相色谱 - 串联质谱法(HPLC - MS/MS),用于同时测定人血浆中的依那普利和依那普利拉。以苯那普利为内标,样品预处理采用0.2 ml血浆一步甲醇蛋白沉淀法(PPT)。分析在Ultimate XB - C(18)柱(50 mm×2.1 mm,内径,3μm)上进行,流动相由甲醇 - 水 - 甲酸(62:38:0.2,v/v/v)组成。检测在三重四极杆串联质谱仪上通过电喷雾电离(ESI)源的多反应监测(MRM)模式进行。每个血浆样品在2.5分钟内完成色谱分析。依那普利和依那普利拉的线性校准曲线在0.638 - 255 ng/ml浓度范围内均获得(r(2)≥0.99),定量下限(LLOQ)为0.638 ng/ml。日内精密度(R.S.D.)低于7.2%,日间R.S.D.小于14%,而准确度(相对误差R.E.)在依那普利和依那普利拉的QC样品测定中分别在±8.7和±5.5%范围内,符合FDA指南要求。本文所述的HPLC - MS/MS方法经过充分验证,并成功应用于20名健康男性志愿者口服马来酸依那普利胶囊后的药代动力学研究。